Technical Analysis for ORMP - Oramed Pharmaceuticals Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | -0.39% | |
| Upper Bollinger Band Touch | Strength | -0.39% | |
| Jack-in-the-Box Bullish | Bullish Swing Setup | -4.48% | |
| Pocket Pivot | Bullish Swing Setup | -4.48% | |
| Inside Day | Range Contraction | -4.48% | |
| Above Upper BB | Strength | -4.48% | |
| Up 3 Days in a Row | Strength | -4.48% |
| Alert | Time |
|---|---|
| Up 2% | about 10 hours ago |
| Up 1% | about 10 hours ago |
| 60 Minute Opening Range Breakdown | 3 days ago |
| Jack-in-the-Box Bullish Entry | 3 days ago |
| Rose Above Previous Day's High | 3 days ago |
Get a Trading Assistant
- Earnings date: 08/08/2024
Oramed Pharmaceuticals Inc. Description
Oramed Pharmaceuticals, Inc., a pharmaceutical company, engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's products primarily comprise ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone that is in per-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Jerusalem, Israel.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Pharmaceutical Diabetes Medication Gastrointestinal Insulin Endocrine System Polyp Peptides Peptide Hormones Treatment Of Diabetes Tablet Glucagon Like Peptide 1 Integrated Security Pharmaceutical Solutions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.67 |
| 52 Week Low | 1.676 |
| Average Volume | 136,344 |
| 200-Day Moving Average | 2.45 |
| 50-Day Moving Average | 2.32 |
| 20-Day Moving Average | 2.29 |
| 10-Day Moving Average | 2.39 |
| Average True Range | 0.15 |
| RSI (14) | 60.47 |
| ADX | 21.05 |
| +DI | 30.54 |
| -DI | 14.65 |
| Chandelier Exit (Long, 3 ATRs) | 2.33 |
| Chandelier Exit (Short, 3 ATRs) | 2.45 |
| Upper Bollinger Bands | 2.62 |
| Lower Bollinger Band | 1.96 |
| Percent B (%b) | 0.91 |
| BandWidth | 29.02 |
| MACD Line | 0.06 |
| MACD Signal Line | 0.01 |
| MACD Histogram | 0.051 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.73 | ||||
| Resistance 3 (R3) | 2.73 | 2.68 | 2.70 | ||
| Resistance 2 (R2) | 2.68 | 2.63 | 2.68 | 2.69 | |
| Resistance 1 (R1) | 2.62 | 2.61 | 2.62 | 2.62 | 2.68 |
| Pivot Point | 2.57 | 2.57 | 2.57 | 2.57 | 2.57 |
| Support 1 (S1) | 2.51 | 2.52 | 2.51 | 2.51 | 2.44 |
| Support 2 (S2) | 2.46 | 2.50 | 2.46 | 2.43 | |
| Support 3 (S3) | 2.40 | 2.46 | 2.42 | ||
| Support 4 (S4) | 2.40 |
